Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted FCF Margin of 9281.13% for Q4 2024, up 192.92% on a QoQ basis from 9988.22% in Q3 2024, and up 926897.0% year-over-year from N/an in Q1 2024.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals has reported FCF Margin for 4 years, with the latest figure at 9281.13% in Q4 2024.
- On a quarterly basis, FCF Margin rose 926897.0% year-over-year to 9281.13% in Q4 2024; TTM through Sep 2025 was 24295.6%, a 2434374.0% increase from a year earlier, with the FY2024 full-year figure at 192.0%, down 19480.0% from the prior year.
- FCF Margin was 9281.13% for Q4 2024 at Amylyx Pharmaceuticals, up from 9988.22% in the prior quarter.
- The five-year high for FCF Margin was 9281.13% in Q4 2024, with the low at 12619.42% in Q3 2022.
- Average FCF Margin over 4 years is 2494.63%, with a median of 7.45% recorded in 2023.
- The sharpest annual moves came in 2023 and 2024: FCF Margin surged 1261404 bps in 2023, then plunged 998284 bps in 2024.
- Over 4 years, FCF Margin stood at 7374.74% in 2021, then surged by 97 bps to 229.92% in 2022, then surged by 105 bps to 12.17% in 2023, then jumped by 76181 bps to 9281.13% in 2024.
- The last three FCF Margin figures came in at 9281.13% (Q4 2024), 9988.22% (Q3 2024), and 6517.01% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -18,629.40% |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 9,281.13% |
| Sep 30, 2024 | -9,988.22% |
| Jun 30, 2024 | -6,517.01% |
| Mar 31, 2024 | -0.63% |
| Dec 31, 2023 | 12.17% |
| Sep 30, 2023 | -5.38% |
| Jun 30, 2023 | 8.48% |
| Mar 31, 2023 | -7.45% |
| Dec 31, 2022 | -229.92% |
| Sep 30, 2022 | -12,619.42% |
| Sep 30, 2021 | -7,374.74% |